Actualités et vidéos - JP MORGAN CHASE & CO. - Page 3

Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire INCHEON, South Korea, Jan. 14, 2025 Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug developments including...

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference PR Newswire INCHEON, South Korea, Jan. 14, 2025 - The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea , Jan. 14, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy PR Newswire NEW HAVEN, Conn., Jan. 13, 2025 Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDE TM...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com . The webcast...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43 rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15,...

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California. Management will give a presentation on Tuesday, January 14, 2024, at 7:30 AM Pacific Time. A webcast of the presentation will be available on P3’s Investor Relations Website at https://ir.p3hp.org/ . A replay will be available on...

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 13, 2025 Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 13, 2025 – PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started...

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate...

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire BURLINGTON, N.C., Jan. 10, 2025 BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14 , at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor...

Areteia Therapeutics, Inc. (« Areteia »), une société de biotechnologie au stade clinique qui développe de nouvelles thérapies d'inflammation et d'immunologie, en se focalisant en premier lieu sur l'asthme éosinophile sévère, a annoncé aujourd'hui que la société allait faire un exposé lors de la 43 e conférence annuelle sur les soins médicaux de J.P. Morgan, le mardi 14 janvier 2025 à 13 h 30 (heure de Pacifique) à San Francisco, en Californie. Une copie de la présentation sera...

Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference PR Newswire HANGZHOU, China, Jan. 9, 2025 HANGZHOU, China , Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025 . HgC CEO Gary Xu and Apeloa VP George Cai will be present along with their teams to connect with industry...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00...

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire BOSTON, Jan. 9, 2025 BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly , is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT ( 1:30 p.m. ET ). Further details, a webcast link,...

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire BRIDGEWATER, N.J., and BENGALURU, India, Jan. 9, 2025 BRIDGEWATER, N.J. , and BENGALURU, India , Jan. 9, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL) , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 in San Francisco, CA. Shreehas Tambe, Chief...

EQS-News: JPMorgan ETFs (Ireland) ICAV / Key word(s): Dividend Dividend Declaration 09.01.2025 / 12:00 GMT/BST The issuer is solely responsible for the content of this announcement. COMPANY ANNOUNCEMENT For Immediate Release 09 January 2025 JPMorgan ETFs (Ireland) ICAV RE: Dividends The Directors of JPMorgan ETFs (Ireland) ICAV (the "Company") wish to announce the following dividends which are ex dividend as of the 16 January 2025, record date as of the 17 January 2025 & payment date is the 07...

EQS-News: JPMorgan ETFs (Ireland) ICAV / Schlagwort(e): Dividende Dividendenmitteilung 09.01.2025 / 12:00 GMT/BST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Die Geschäftsführung des JPMorgan ETFs (Ireland) ICAV (die “Gesellschaft”) kündigt hiermit folgende Dividenden an, für die als Ex-Dividendendatum der 16. Januar 2025 gilt. Stichtag ist der 17. Januar 2025 und das Zahlungsdatum ist der 07. Februar 2025: Beschreibung der Anteilsklasse ISIN Satz je...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that management will participate at the 43 rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentation will be accessible from the Investor...

LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13 th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference. The J.P. Morgan Healthcare Conference is the industry's leading...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT). A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed...